Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2019 /
Use of maintenance therapy following ASCT and real world treatment patterns in multiple myeloma

13th - 16th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
This video is restricted to members who are registered with ecancer as a healthcare professional
Please login or register for free to confirm your details.
Published: 15.06.19
Views: 1519

Dr Evangelos Terpos, Prof Michele Cavo, Dr Eloísa Riva, Dr Fredrik Schjesvold

Dr Evangelos Terpos (University of Athens, Athens, Greece), Prof Michele Cavo (University of Bologna, Bologna, Italy), Dr Eloísa Riva (Hospital de Clínicas, Montevideo, Uruguay) and Dr Fredrik Schjesvold (Oslo University Hospital, Oslo, Norway) discuss the deepening response seen with the use of ixazomib as a maintenance therapy following autologous stem cell transplantation - as demonstrated in the TOURMALINE-MM3 study in patients with multiple myeloma.

The panel also highlight the main considerations for the use of this type of therapy and how quality of life may be impacted - as explained by Dr Schjesvold.

The session concludes with the discussion of evolving treatment patterns in the real world from a global perspective; with a mention of unfit and elderly patients.

Ixazomib maintenance therapy post-autologous stem cell transplantation
Discussion of impact on everyday clinical practice
Quality of life outcomes of ixazomib
Recommendations for lenalidomide maintenance
Management of high risk disease
Double autologous stem cell transplantation
Real world data vs clinical trials
Practice changing data from EHA 2019

This programme has been supported by an unrestricted educational grant from Takeda.



Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation